ArticleClinical rheumatology2022

Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis.

Chongqing Tan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.